Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib Switch in CML-CP Patients Intolerant or Suboptimally Responsive to Other TKIs
ChiCTR2000039224Phase 4Recruiting
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Major Molecular Response. Started Oct 2020; status: recruiting.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2000039224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039224.